HeartWare International — Shareholder Meeting (May 2008)
22 slides from HeartWare International's shareholder meeting presentation, May 8, 2008
Slide 1: CEO Presentation 2008 AGM
HeartWare Limited (ASX:HTW) » Doug Godshall CEO Presentation 2008 AGM
Slide 2: Topics
Topics Year in Review Opportunity Update Clinical/Regulatory Status Pipeline Review Financials
Slide 3: Since last AGM Achieved
Since last AGM Achieved: Completed 20 patient enrollment Extended to 30 and again to 50 Received conditional IDE approval Presented data at ISHLT meeting Conducted multiple MVAD preclinical studies and refined design concepts Advanced TETS to working prototype Secured upgraded new facility and comme
Slide 4: Heart Failure is a significant problem for society
Heart Failure is a significant problem for society A degenerative and terminal disease Affects over 20 million people globally (5+ million in the US) 1 million new cases diagnosed every year 300,000 deaths per year in the US At least 1 million patients in NYHA Class IV, the end-stage of the disease
Slide 5: Heart Failure is Fatal
Heart Failure is Fatal AHA update, January 2008 Cause # Deaths in '04 Heart Failure 284,000 Heart Attack 158,000 Stroke 150,000 Diabetes 73,000 Aids 13,000 75% of HF patients under age 65 will die within 8 years HF kill 7 times more people than breast cancer annually 1 in 8 death certificates in US
Slide 6: LVAD's are the only viable option for most
LVAD's are the only viable option for most Heart transplantation is a proven therapy, but availability is severely limited Fewer than 4,000 donor hearts annually Many patients ineligible for transplantation Alternative therapies not delivering on initial promise Drugs & pacing do not halt disease pr
Slide 7: Acceleration in 2008
Acceleration in 2008 Market growth now in double digits Technology: significant improvements Thoratec HMII approved in US April '08 - first new pump since 1998 HeartWare entering EU 2H 2008 Experience: transplant programs more experienced Outcomes improving worldwide Economics: US reimbursement incr
Slide 8: HeartWare's advantages resonating worldwide
HeartWare's advantages resonating worldwide Reprinted with permission from Thoratec Corporation Abdominal (Others) Pericardial (HeartWare)
Slide 9: Size REALLY matters
Size REALLY matters The HeartWare(r) LVAD is the only full output pump implantable within the pericardial space in all patients No abdominal surgery No pump pocket drains No pump pocket infections No GI distress related to abdominal organ pressure Reduced procedural invasiveness and complexity Short
Slide 10: Entire system required to win
Entire system required to win Surgeons Cardiologists Patients Factors Easy to implant Avoid pump pocket Minimal re-intervention Minimal "fiddle factor" Infrequent re-admissions "Out of sight out of mind" Intuitive peripherals Low complication rates Good battery life "Normal" life HeartWare
Slide 11: US IDE trial
US IDE trial Received conditional approval for BTT protocol on May 1 Novel trial design Utilizing NIH funded control arm (Intermacs Registry) First Bridge study to be permitted "survival" as endpoint versus "listed for transplant" Immediate patient discharge permitted No safety phase required; strai
Slide 12: International CE Mark clinical trial
International CE Mark clinical trial Trial enrolment completed August 2007 (20 patients) Extension approved to allow up to 50 patients (currently 32) Primary endpoint is survival to 180 days or transplant Submission of Technical Dossier expected 2H 2008
Slide 13: Promising clinical results
Promising clinical results Dr George Wieselthaler, Principal Investigator at Vienna General Hospital, with three of his HeartWare patients 91% Survival presented at ISHLT 32 implants Cumulative support >7500 days (20+ yrs) Average duration of support >230 days per patient Successful completion of pr
Slide 14: Outcomes at 180 Days for First Implants
Outcomes at 180 Days for First 23 Implants At 180 days: Survival - 91% Transplant- 10% Recovery - 0% Death - 9% *Presented by G Wieselthaler, MD at the ISHLT Annual Meeting, Boston, MA, April 12, 2008
Slide 15: BTT: Improvement in Survival over time
BTT: Improvement in Survival over time 0 1 2 3 4 5 6 7 8 9 10 11 12 HM XVE 100 81 76 74 71 70 69 68 68 65 60 57 55 HeartMate II 100 90 86 80 80 75 75 72 72 72 72 68 68 HeartWare 100 94 94 90 90 90 90 84 84 84 84 84 84 Months Post Op % Survival 1997 2005 2008 91 75 60 Multicenter clinical evaluation
Slide 16: What do HeartWare patients do post implant?
What do HeartWare patients do post implant? Sing opera Play tennis Play soccer Travel Return to work Raise their families Practice Law Play in chess tournaments Walk the dog Live normal lives
Slide 17: Getting bigger by getting smaller
Getting bigger by getting smaller Procedure Surgical Minimally Invasive Catheter Delivery System Flow 10 L/min 7 L/min 3 L/min Patient Class Late Class IV Class III & IV Class III Treatable Pop. 100,000 350,000 1,000,000 Current status: IDE Preclinical studies Prototype and exploratory
Slide 18: MVAD showing promise and versatility
MVAD showing promise and versatility Developing implant techniques that avoid sternotomy MVAD seems to work wherever we place it Goals are: Small incision Decrease complications Increase number of patients who can benefit Will select "winner" in 2008 Full project kick off in 2009 First implant likel
Slide 19: The next major advance: TETS
The next major advance: TETS Transcutaneous Energy Transfer showing significant progress Enables transfer of energy and information across the skin Replaces driveline cable and eliminates risk of driveline complications Enables patient to be un-tethered from the charging system for extended periods
Slide 20: Key Upcoming Milestones
Key Upcoming Milestones Milestone Timing Status Submissions of IDE to US FDA Q4 2007 Extension of International Trial to allow additional implants Q4 2007 Approval to Commence US trial Q2 2008 Submission of Technical Dossier to Competent Authority 2H 2008 On Target Receipt of CE Mark (European Regul
Slide 21: Financial snapshot
Financial snapshot Cash on hand ~ AU$24.9M (31, March) Burn rate ~ AU$2-2.2M per month First revenue Anticipated mid 2008 Shares on issue ~ 248M Market Cap ~ $120M Number of employees 92 Top 20 shareholders >75% of shares
Slide 22: Summary
Summary Heart Failure is a disease of epidemic proportions Market acceleration is underway HeartWare is well positioned to benefit from market growth now and will be the primary driver of dramatic growth in the future Commercialization to commence in mid-2008